Drugs / IRL201104
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT05921591 | May → Sep 2023 | — | Revolo Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04748536 | Jan → Apr 2021 | — | Revolo Biotherapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03058458 | Jan 2017 → Jan 2018 | asthma | Peptinnovate | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT05098522 | Nov 2021 → Mar 2023 | seasonal allergic rhinitis | Revolo Biotherapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05084963 | Oct 2021 → Oct 2022 | eosinophilic esophagitis | Revolo Biotherapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-02-04 | Revolo Biotherapeutics | Results Revolo to Present at the 2026 AAAAI Annual Meeting revolobio.com ↗
Dr. De Alba will discuss how ‘1104 has now shown therapeutic potential in a model of atopic dermatitis through the intravenous (IV), subcutaneous (SC), and sublingual (SL) routes of administration. |
| 2025-02-10 | Revolo Biotherapeutics | Results Revolo to Present at the 2025 AAAAI / WAO Joint Congress revolobio.com ↗
In a chronic allergen-driven murine model of AD, ‘1104 significantly reduced skin thickness and skin pathology indicators. |
| 2022-05-16 | Revolo Biotherapeutics | Results Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings revolobio.com ↗
Treatment with ‘1104 resulted in a long-lasting dose response through both IV and SC administration |
| 2022-02-25 | Revolo Biotherapeutics | Results Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome revolobio.com ↗
‘1104 showed a marked anti-inflammatory effect to treatment which was comparable with current standard of care with the steroid dexamethasone in a murine model. |
| 2019-12-10 | Revolo Biotherapeutics | Results Immune Regulation presents new data on ‘1104 at the American Thoracic Society (ATS) Annual International Conference revolobio.com ↗
‘1104 significantly inhibited eosinophil recruitment to the lung 24 hours after sensitization and 10 days after the last treatment on rechallenge. |
| 2019-11-26 | Revolo Biotherapeutics | Results Immune Regulation announces positive results from Phase 1 clinical trial of IRL201104 revolobio.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRL201104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05084963 ↗ |
| Known as | PIN201104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03058458 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068613 ↗ |
| Route | Intravenous | “IV or SC administration” NCT03058458 ↗ |
| Route | Subcutaneous | “IV or SC administration” NCT03058458 ↗ |